Navigation Links
China YCT International Group, Inc. Announces Entrusted Management Agreement With Its Primary Supplier
Date:4/7/2008

NEW YORK, April 7, 2008 /Xinhua-PRNewswire-FirstCall/ -- China YCT International Group Inc. (OTC Bulletin Board: CYIG) today announced that its wholly owned subsidiary, Shandong Spring Pharmaceutical Co., Ltd, has entered into an Entrusted Management Agreement with Shandong Yong Chun Tang Bioengineering Co. Ltd., effective as of April 4, 2008. The agreement provides that Shandong Spring Pharmaceutical will manage the operations of Shandong Yong Chun Tang, in exchange for all of the net profits earned by Shandong Yong Chun Tang. Shandong Yong Chun Tang is the primary supplier of products marketed by Shandong Spring Pharmaceutical. The companies also announced that they intend to enter into a strategic relationship to integrate and distribute Shandong Yong Chun Tang's gingko products using Shandong Spring Pharmaceutical's advanced logistics solutions.

At the same time, the parties entered into a Purchase Option and Cooperation Agreement with Yan Tinghe, who is the Chairman of China YCT International Group, Inc. and principal owner of Shandong Yong Chun Tang. The Purchase Option gives Shandong Spring Pharmaceutical the right to purchase Shandong Yong Chun Tang at a fair value price to be determined by the parties at the time the option is exercised. Mr. Yan also gave to Shandong Spring Pharmaceutical a proxy to exercise his voting rights as a shareholder of Shandong Yong Chun Tang.

Commenting on the announcement, Yan Tinghe, Chairman of China YCT International Group, Inc., said, "Today's agreement accomplishes our goal of focusing our organization, while also establishing a long-term relationship with Shandong Spring Pharmaceutical., Ltd that will be beneficial to both companies. Our newly distribution management team, professional staff, and financial resources can now concentrate on establishing meaningful market share, awareness, and industry appreciation for gingko products."

Commenting on the synergies of the companies' planned strategi
'/>"/>

SOURCE China YCT International Group Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. China Kangtai Cactus Biotech Files 2nd Quarter 2007 10QSB and Announces Unaudited Quarterly Results
2. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
3. China Medical Technologies to Participate in the Morgan Stanleys 2007 China Medical Corporate Day
4. China-Biotics, Inc. Signs Intention Agreement to Supply Probiotics to Bright Dairy & Food Co., Ltd.
5. China Technology Announces New Chief Financial Officer
6. China Medical Technologies Reports First Quarter Financial Results
7. China Medical Technologies to Participate in Credit Suisses 2007 Asian Technology Conference
8. China Technology Announces Entry to the Solar Energy Sector
9. China Sky One Medical Receives $1.5 Million Government Grant to Further Develop Six New Cancer Products
10. Kiwa Bio-Tech Named Recommended Brand by the China Green Food Association
11. China Kangtai Cactus Biotech, Inc. Announces Plans for New Product Launch

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/24/2009)...-ShanghaiBiolaxyannouncedthe,ChineseStateFood&...onalnewdrugapplication(IND)foritsoralinsulinprojec...abetes.ThisIND,approvalallowsBiolaxytoinitiateitsf...rcharacteristicofhighbloodglucoseandpoor,metabolis...ro-and,macro-vasculardiseases,lossofvision,kidneyf...
(Date:11/24/2009)...forpatientswithadvanced-stage,orrecurrentendometri...tCall/-AEternaZentarisInc.(NASDAQ: AEZS ;TSX:AEZ)(...edonendocrinetherapyandoncology,todayannouncedposi...otoxicpeptideconjugate,AEZS-108(formerlyAN-152),in...napersonalizedhealthcareapproach,thestudyselectedp...
(Date:11/24/2009)...irstCall/--ArenaPharmaceuticals,Inc.(Nasdaq: ARNA ...tatthePiperJaffray21stAnnualHealthCareConferenceon...icTime)attheNewYorkPalaceHotelinNewYorkCity.JackLi...heduledtoprovideanoverviewofthecompany,includingit...iveaudiowebcastofthepresentationwillbeavailableund...
(Date:11/24/2009)...s Customers with Partners Validated to Process and...ts , Ottawa, ON (PRWEB) N...der of products for biological sample collection, ... new global partner program. The program offers si...ommunity and is designed to help partners scale an...
Breaking Biology Technology:Biolaxy Secures IND Approval for Oral Insulin 2AEterna Zentaris Announces Positive Results for Phase 2 Study with LHRH-Receptor Targeted Cytotoxic Conjugate AEZS-108 in Endometrial Cancer 2AEterna Zentaris Announces Positive Results for Phase 2 Study with LHRH-Receptor Targeted Cytotoxic Conjugate AEZS-108 in Endometrial Cancer 3AEterna Zentaris Announces Positive Results for Phase 2 Study with LHRH-Receptor Targeted Cytotoxic Conjugate AEZS-108 in Endometrial Cancer 4Arena Pharmaceuticals to Present at the Piper Jaffray 21st Annual Health Care Conference 2DNA Genotek Launches Global Partner Program 2DNA Genotek Launches Global Partner Program 3
...ord of Investment Success -, GAITHERSBURG, Md., J...rldwide biologics unit of AstraZeneca plc (LSE: AZ...uccessful venture capital fund,MedImmune Ventures,...gic,interest to both organizations by adding the t...isease, pain and central nervous system,disorders ...
...Jan. 7 /Xinhua-PRNewswire-FirstCall/ --,Kiwa Bio-T... that: Xinjiang,Corps Agro-technology Extended Ter...lizer products "Pen Duo Shou" and "Jin Peng Jia Ba...The new official fertilizer,certificate replaces t...egistration Certificate., In 2007, Xinjiang Corps...
...gland, January 7 /PRNewswire-FirstCall/,-- Evotec ... that it has,successfully completed a Phase I safe...inary results confirm the good tolerability profil...her clinical development., EVT 302, a reversible ...ment for smoking cessation, was investigated in an...
Other Biology Technology:MedImmune Broadens Focus of Venture Capital Fund to Include New Therapeutic Areas 2MedImmune Broadens Focus of Venture Capital Fund to Include New Therapeutic Areas 3Kiwa Fertilizers Pass Independent Tests 2Kiwa Fertilizers Pass Independent Tests 3Phase I Safety and Tolerability Study With EVT 302 Successfully Completed 2Phase I Safety and Tolerability Study With EVT 302 Successfully Completed 3Phase I Safety and Tolerability Study With EVT 302 Successfully Completed 4Phase I Safety and Tolerability Study With EVT 302 Successfully Completed 5
(Date:11/23/2009)...TORONTO, November 23, 2009 - The time of day matte... to a new paper produced by a research team led by... Scarborough,s vice-principal for research and col...ogy at the St. George campus. , Capitalizing o...poplar tree, the research team examined how poplar...
(Date:11/23/2009)...CHAMPAIGN, Ill. A new study provides "incontrover...f Toba on the island of Sumatra about 73,000 years...miles from the epicenter, researchers report. , ...ers of ash into the atmosphere, leaving a crater (... kilometers long and 35 kilometers wide. Ash from ...
(Date:11/23/2009)..., BIRMINGHAM, Ala. A new study by University of A...body-mass index (BMI) and co-existing medical cond... survival observed among African-Americans compare...udy is published online Nov. 23 in Cancer , a jou...ng indicates that although BMI and co-morbidity ar...
Breaking Biology News(10 mins):Time of day matters to thirsty trees, U of T researcher discovers 2Supervolcano eruption -- in Sumatra -- deforested India 73,000 years ago 2Racial disparity in colon cancer survival not easily explained, UAB researchers say 2Pelosi Statement on Senate Health Insurance Reform Bill 61677 1Opto electronic nose sniffs out toxic gases 14911 1Opto electronic nose sniffs out toxic gases 14911 2Opto electronic nose sniffs out toxic gases 14911 3Universal Health Services Inc Announces Stock Split and Cash Dividend Increase 61672 1
...s from infectious diseases in hurricane-devastated...ommon infections rather than exotic diseases. Thes...imple hygiene measures and a little common sense. ...e unlikely to break out after hurricanes and flood...urally occur," says Ruth Berkelman, MD, Chair of t...
...scovery that will advance our understanding of how...st cancer cells. The research, in collaboration wi...ues de Montreal (IRCM) identifies 153 genes that r...be used to halt the growth of breast cancer cells....e National Academy of Sciences (PNAS), will focus ...
...ur finger on a hot stove? Imagine what it,s like t... the time and know there,s virtually nothing you c...d it,s a common complication of many diseases and ...e little effect on this type of pain, which is cau...n, temperature and touch signals to and from the b...
Other Biology News:Hurricane aftermath: Infectious disease threats from common, not exotic, diseases 2Scientists discover genetic pathway responsible for breast cancer cell growth 2Scientists use gene transfer technology and common virus to block neuropathic pain 2Scientists use gene transfer technology and common virus to block neuropathic pain 3Scientists use gene transfer technology and common virus to block neuropathic pain 4
Rabbit Anti-HES1 Antibody, Unconjugated from ABR-Affinity BioReagents
Rat Anti-Mouse Endoglin Monoclonal Antibody, Fluorescein Conjugated, Clone 209701 from R&D Systems
Caspase Inhibitor Ac-DEVD-CHO, Unconjugated from Promega
Coriolis equipment from Bertin Technologies
Biology Products: